Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lowered its position in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) by 28.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,618 shares of the biotechnology company’s stock after selling 43,889 shares during the period. Russell Investments Group Ltd.’s holdings in Eiger BioPharmaceuticals were worth $932,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Eiger BioPharmaceuticals in the first quarter valued at about $39,000. Forefront Analytics LLC acquired a new stake in Eiger BioPharmaceuticals in the first quarter valued at about $97,000. Oppenheimer & Co. Inc. acquired a new stake in Eiger BioPharmaceuticals in the first quarter valued at about $136,000. HRT Financial LP acquired a new stake in Eiger BioPharmaceuticals in the first quarter valued at about $165,000. Finally, Axiom Investment Management LLC acquired a new stake in Eiger BioPharmaceuticals in the first quarter valued at about $186,000. Hedge funds and other institutional investors own 68.68% of the company’s stock.

Shares of Eiger BioPharmaceuticals stock opened at $7.03 on Tuesday. The company has a current ratio of 7.48, a quick ratio of 7.35 and a debt-to-equity ratio of 0.29. The company has a 50-day moving average of $8.01 and a two-hundred day moving average of $8.37. Eiger BioPharmaceuticals, Inc. has a 12-month low of $6.80 and a 12-month high of $13.49. The stock has a market cap of $238.68 million, a PE ratio of -8.79 and a beta of 1.34.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.03). On average, sell-side analysts forecast that Eiger BioPharmaceuticals, Inc. will post -2.84 EPS for the current fiscal year.

A number of research analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $45.00 target price on shares of Eiger BioPharmaceuticals in a report on Friday, August 6th. Citigroup increased their target price on shares of Eiger BioPharmaceuticals from $26.00 to $27.00 and gave the company a “buy” rating in a report on Monday, August 9th. Finally, Zacks Investment Research cut shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 10th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $26.17.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Featured Story: What are the reasons investors use put options?

Want to see what other hedge funds are holding EIGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR).

Institutional Ownership by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.